Status:
COMPLETED
Intravenous Voriconazole in Patients With Renal Compromise
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
Pfizer
Conditions:
Renal Transplant
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine whether patients with compromised renal function (CrCl \< 50mL/min) receiving intravenous voriconazole experienced any adverse effects related to serum chemis...
Detailed Description
The purpose of this study is to determine whether patients with compromised renal function (CrCl \< 50mL/min) receiving intravenous voriconazole experienced any adverse effects related to serum chemis...
Eligibility Criteria
Inclusion
- \- Patients \> 18 years old receiving voriconazole with a serum creatinine of \> 2mg/dl (a proxy marker for Creatinine clearance \< 50ml/min). Control group in this study will have serum creatinine \< 1.5mg/dl. Solid organ transplant patient. Patient that received at least 2 doses of voriconazole.
Exclusion
- None
Key Trial Info
Start Date :
May 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00332410
Start Date
May 1 2006
End Date
December 1 2015
Last Update
June 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213